In:
Journal of Cardiovascular Pharmacology and Therapeutics, SAGE Publications, Vol. 6, No. 4 ( 2001-12), p. 363-367
Abstract:
Background: The concurrent use of amiodarone and warfarin inhibits metabolism of S-war-farin by cytochrome P450 (CYP) 2C9, thereby increasing the anticoagulant effect of war-farin. Amiodarone primarily inhibits CYP1A2 and CYP3A4, and desethylamiodarone primarily inhibits CYP2C9. We investigate whether a relationship exists between the plasma concentration of desethylamiodarone and anticoagulation when amiodarone is administered to patients receiving warfarin therapy. Methods and Results: The correlation between the plasma concentration of either amiodarone or desethylamiodarone, and prolongation of prothrombin time-international normalized ratio/dose of warfarin (A INR/Dose) on day 7 of amiodarone administration was studied in 25 patients (22-74 years old) with structural heart disease and refractory arrhythmias receiving stable warfarin therapy. Results: No correlation was found between the plasma concentration of amiodarone and A INR/Dose, but a correlation was found between the plasma concentration of desethylamiodarone and A INRIDose. Conclusions: It was suggested that inhibition of CYP2C9 by desethylamiodarone, the active metabolite of amiodarone, plays an important role in the interaction of warfarin and amiodarone.
Type of Medium:
Online Resource
ISSN:
1074-2484
,
1940-4034
DOI:
10.1177/107424840100600405
Language:
English
Publisher:
SAGE Publications
Publication Date:
2001
detail.hit.zdb_id:
1329372-2
detail.hit.zdb_id:
2230155-0
Permalink